Diagnostic value of endothelial markers and HHV-8 staining in gastrointestinal Kaposi sarcoma and its difference in endoscopic tumor staging

Naoyoshi Nagata, Toru Igari, Takuro Shimbo, Katsunori Sekine, Junichi Akiyama, Yohei Hamada, Hirohsa Yazaki, Norio Ohmagari, Katsuji Teruya, Shinichi Oka, Naomi Uemura

Naoyoshi Nagata, Katsunori Sekine, Junichi Akiyama, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Toru Igari, Department of Clinical pathology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Takuro Shimbo, Department of Clinical Research and Informatics, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Yohei Hamada, Hirohsa Yazaki, Katsuji Teruya, Shinichi Oka, Division of AIDS Clinical Center (ACC), National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Norio Ohmagari, Department of Infectious disease, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Naomi Uemura, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba 272-8516, Japan

Author contributions: Nagata N participated in the design of the study, data acquisition and interpretation, performed endoscopy, and wrote the manuscript; Shimbo T participated in the design of the study and contributed to statistical analyses; Igar T evaluated pathological diagnosis and infection; Sekine K, Hamada Y, and Yazaki H, helped with data acquisition; Ohmagari N, Akiyama J, Teruya K, Oka S and Uemura N advised on the design of the study and contributed to the writing of the manuscript; all authors read and approved the submitted version of the manuscript.

Supported by: A Grant from the National Center for Global Health and Medicine (21-101)
Correspondence to: Naoyoshi Nagata, MD, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, 162-8655, Tokyo, Japan, nnagata_ncgm@yahoo.co.jp
Telephone: +81-3-32027181 Fax: +81-3-32071038
Received: February 16, 2013 Revised: April 4, 2013 Accepted: April 9, 2013 Published online: June 21, 2013

Abstract

Aim: To clarify the diagnostic values of hematoxylin and eosin (HE), D2-40, CD31, CD34, and HHV-8 immuno-histochemical (IHC) staining in gastrointestinal Kaposi’s sarcoma (GI-KS) in relation to endoscopic tumor staging.

Methods: Biopsy samples (n = 133) from 41 human immunodeficiency virus-infected patients were reviewed. GI-KS was defined as histologically negative for other GI diseases and as a positive clinical response to KS therapy. The receiver operating characteristic area under the curve (ROC-AUC) was compared in relation to lesion size, GI location, and macroscopic appearances on endoscopy.

Results: GI-KS was confirmed in 84 lesions (81.6%). Other endoscopic findings were polyps (n = 9), inflammation (n = 4), malignant lymphoma (n = 4), and condyloma (n = 2), which mimicked GI-KS on endoscopy. ROC-AUC of HE, D2-40, blood vessel markers, and HHV-8 showed results of 0.83, 0.89, 0.80, and 0.82, respectively. For IHC staining, the ROC-AUC of D2-40 was significantly higher (P < 0.05) than that of HE staining only. In the analysis of endoscopic appearance, the ROC-AUC of HE and IHC showed a tendency toward an increase in tumor staging (e.g., small to large, patches, and polypoid to SMT appearance). D2-40 was significantly (P < 0.05) advantageous in the upper GI tract and for polypoid appearance compared with HE staining.

Conclusion: The diagnostic value of endothelial markers and HHV-8 staining was found to be high, and its accuracy tended to increase with endoscopic tumor staging. D2-40 will be useful for complementing HE staining in the diagnosis of GI-KS, especially in the upper GI tract and for polypoid appearance.

Key words: Gastrointestinal Kaposi’s sarcoma; Hematoxylin and eosin; CD31; CD34; D2-40; Human herpesvirus-8
Core tip: Diagnosis of gastrointestinal Kaposi sarcoma (GI-KS) is important because treatment specifics depend on the extent of the disease. Endoscopic biopsy is a definitive diagnostic method for GI-KS, but its diagnostic accuracy has not been fully studied. In the current study, receiver operating characteristic area under the curve of hematoxylin and eosin (HE) staining, lymphatic and blood vessel endothelial cell markers, and HHV-8 was found to be high (> 0.80), and its accuracy tended to increase with endoscopic tumor staging. D2-40 will be useful for complementing HE staining in the diagnosis of GI-KS, especially in the upper GI tract and for polypoid appearance.

INTRODUCTION

Kaposi sarcoma (KS) is a rare cancer that was highly prevalent in the early stages of the acquired immune deficiency syndrome (AIDS) epidemic. Although the rate of KS has shown a marked reduction since the introduction of highly active antiretroviral therapy (HAART), KS remains the most common malignancy in patients with AIDS.

KS primarily involves the skin but can also involve the viscera. Because the need for treatment and choice of treatment depend on visceral involvement, diagnosis of the gastrointestinal (GI) tract, a common site of visceral involvement, is important. Definitive diagnosis of GI-KS requires endoscopic biopsy, but GI-KS often presents on endoscopy with submucosal or small protruded appearance, which can lead to false-negative biopsy results.

Recently, immunohistochemical (IHC) staining with D2-40, CD31, CD34, and HHV-8 has been reported as effective in the diagnosis of GI-KS, but its diagnostic accuracy has not been fully studied. In the current study, receiver operating characteristic area under the curve of hematoxylin and eosin (HE) staining, lymphatic and blood vessel endothelial cell markers, and HHV-8 was found to be high (> 0.80), and its accuracy tended to increase with endoscopic tumor staging. Therefore, IHC staining in addition to HE staining was performed.

Nagata N, Igari T, Shimbo T, Sekine K, Akiyama J, Hamada Y, Yazaki H, Ohmagari N, Teruya K, Oka S, Uemura N. Diagnostic value of endothelial markers and HHV-8 staining in gastrointestinal Kaposi sarcoma and its difference in endoscopic tumor staging. World J Gastroenterol 2013; 19(23): 3608-3614 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i23/3608.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i23.3608

MATERIALS AND METHODS

Subjects

We retrospectively reviewed histologic slides from 103 consecutive lesions for which IHC staining was performed between 2006 and 2012 at the National Center for Global Health and Medicine (NCGM). Lesions were obtained from 41 human immunodeficiency virus (HIV)-infected patients who had not received anti-KS therapy. The institutional review board at NCGM approved this study.

Clinical factors

Sexual behavior was classified subjects into two groups: men who have sex with men (MSM); and heterosexual. CD4+ cell counts and HIV-RNA viral load (VL) determined by real-time quantitative polymerase chain reaction (PCR) were reviewed within 1 mo of endoscopy. A positive result for real-time HIV-RNA was defined as ≥ 40 copies/mL. History of HAART was collected from medical records prior to endoscopy. GI symptoms were assessed by the physician who interviewed each patient. Those without GI symptoms and negative screening endoscopy were considered to be symptom-free.

Diagnosis of GI-KS

Confirmed GI-KS lesions were defined as those that fulfilled with following criteria. (1) Histologically negative biopsy for other GI diseases; (2) A positive response to KS therapy (HAART or systemic therapy of liposomal anthracycline); and (3) partial or complete resolution was confirmed on follow-up endoscopy after KS therapy (Figure 1). We usually perform endoscopy after 1 mo, 2 mo, or 6 mo of KS therapy to evaluate GI-KS regression.

Endoscopic assessment

Endoscopic images were taken using a high-resolution scope (model GFH260, CFH260A; Olympus Optical, Tokyo, Japan) in all patients. We performed a biopsy using biopsy forceps (FB-240U, FB230-K, Olympus Co., Tokyo, Japan).

Size (< 10 mm or ≥ 10 mm), GI location, and macroscopic findings were assessed endoscopically. Locations of GI involvement were classified as upper GI (esophagus, stomach, and duodenum) and lower GI (ileum, colon, and rectum).

Macroscopic findings were evaluated as the presence of reddish mucosa with patches (Figure 2A), polypoid lesions (Figure 2B), submucosal tumor (SMT) (Figure 2C), and ulcerative SMT (Figure 2D), as previously reported. Ulceration was defined endoscopically as a distinct, visible crater > 5 mm in diameter with a slough base.
**Histological assessment**

The presence of proliferating spindle cells with vascular channels filled with blood cells (Figure 3A) from biopsy specimens was evaluated with HE staining by an investigator blinded to IHC staining results. IHC staining for the lymphatic vessel endothelial cell marker D2-40 (Dako North America, Carpentaria, CA) (Figure 3B) and the blood vessel endothelial cell markers CD31 (Dako North America) or CD34 (Dako North America) (Figure 3C), and the use of the mouse monoclonal antibody against HHV-8 LNA-1 (Novocastra Laboratories Ltd, Newcastle upon Tyne, United Kingdom) (Figure 3D), were also evaluated on formalin-fixed, paraffin-embedded tissue sections as previously reported\(^{[19-28]}\). IHC slides were evaluated at × 200 and × 400 magnification by expert GI pathologists.

**Statistical analysis**

To elucidate the accuracy of HE and IHC staining for the diagnosis of GI-KS, the sensitivity, specificity, positive and negative likelihood ratio (LR+ and LR−, respectively), and area under the receiver operating characteristic curve (ROC-AUC) were calculated and estimated with a 95%CI.

The difference of the ROC-AUC of the four specific stains (HE, D2-10, vessel markers, and HHV-8) was compared. Subgroup analysis was performed to identify differences in four specific stains according to gross ap-
Results

Baseline clinical characteristics

All 41 HIV-infected patients were male and the HIV infection route was MSM in all cases. The median CD4 cell count (interquartile range; IQR) was 77 (33, 157) cells/mL and the median HIV viral load (IQR) was 48500 (< 40, 150000) copies/mL. There were 18 (43.9%) patients with a history of HAART. GI symptoms were noted in 10 patients (24.4%). No notable gastrointestinal bleeding or perforation, either spontaneously or after endoscopic biopsy, was noted.

Table 1 provides details on the definitive diagnosis of GI lesions. Of the 103 lesions, 84 (81.6%) were confirmed as GI-KS while the remainder were other GI lesions (19) consisted of hyperplastic polyps (8), fundic grand polyps (1), Helicobacter-associated gastritis (1), malignant lymphoma (4), anorectal condyloma (2), and non-specific colitis (3).

Diagnostic value of specific staining for the diagnosis of GI-KS

Sensitivity, specificity, LR+, LR-, and ROC-AUC of specific staining for the diagnosis of GI-KS are shown in Table 2. The ROC-AUC values of four specific stains (HE, D2-40, blood vessel marker, and HHV-8) were significantly different ($P < 0.01$) in the diagnosis of GI-KS (Table 2). The ROC-AUC of D2-40 staining was only significantly higher ($P < 0.05$) than that of HE staining (Table 2).
Table 2 Diagnostic value of endoscopic biopsy in gastrointestinal Kaposi sarcoma (n = 103)

| KS/non-KS (84/19) | Sensitivity, % (95%CI) | Specificity, % (95%CI) | Positive LR (95%CI) | Negative LR (95%CI) | ROC area2 (95%CI) |
|-------------------|------------------------|------------------------|---------------------|---------------------|------------------|
| HE (59/1)         | 70.2 (59.3-79.7)       | 94.7 (74.0-99.9)       | 9.33 (1.99-43.8)2   | 0.32 (0.23-0.46)2   | 0.83 (0.75-0.90) |
| D2-40 (65/0)      | 77.4 (67.0-85.8)       | 100 (82.4-100)         | 30.8 (1.99-477)2    | 0.24 (0.16-0.35)2   | 0.89 (0.84-0.93) |
| Blood vessel marker (68/4) | 81 (70.9-88.7)   | 78.9 (54.4-93.9)       | 3.85 (1.6-9.24)     | 0.24 (0.15-0.40)    | 0.80 (0.70-0.90) |
| HHV-8 (33/0)      | 63.1 (51.9-73.4)       | 100 (82.4-100)         | 25.2 (1.62-391)2    | 0.36 (0.29-0.51)2   | 0.82 (0.76-0.87) |

LR: Likelihood ratio; HE: Hematoxylin and eosin; HHV: Human herpesvirus. 2Receiver operating characteristic (ROC) area is significantly (P < 0.01) different in this category; 2LR estimated using the substitution formula. A value of 0.5 was added to all cell frequencies before calculation; 3P < 0.05 for comparisons of lesions by HE staining.

Table 3 Diagnostic values of gastrointestinal Kaposi sarcoma in relation to size, location, and macroscopic appearances on endoscopy (n = 103)

| Subgroup | Specific stain | No. of lesions (KS/non-KS) | ROC-AUC (95%CI) | P value |
|----------|----------------|---------------------------|-----------------|---------|
| Size     |                |                           |                 |         |
| Size < 10 mm |                |                           |                 |         |
| HE       | 26/7           | 0.77 (0.67-0.87)           | < 0.01          |         |
| D2-40    | 16/0           | 0.81 (0.71-0.90)           | < 0.01          |         |
| Blood vessel marker | 18/4     | 0.56 (0.34-0.78)           | < 0.01          |         |
| HHV-8    | 10/0           | 0.69 (0.60-0.79)           | < 0.05          |         |
| Size > 10 mm |                |                           |                 |         |
| HE       | 58/12          | 0.85 (0.75-0.94)           | < 0.01          |         |
| D2-40    | 49/0           | 0.92 (0.88-0.97)           | < 0.01          |         |
| Blood vessel marker | 50/0     | 0.93 (0.89-0.98)           | < 0.01          |         |
| HHV-8    | 43/0           | 0.93 (0.89-0.98)           | < 0.01          |         |
| Location |                |                           |                 |         |
| Upper GI tract |            |                           |                 |         |
| HE       | 36/0           | 0.82 (0.75-0.88)           | < 0.01          |         |
| D2-40    | 42/0           | 0.87 (0.81-0.93)           | < 0.01          |         |
| Blood vessel marker | 44/4     | 0.66 (0.48-0.84)           | < 0.01          |         |
| HHV-8    | 36/0           | 0.82 (0.75-0.88)           | < 0.01          |         |
| Lower GI tract |            |                           |                 |         |
| HE       | 25/1           | 0.88 (0.76-1.00)           | < 0.01          |         |
| D2-40    | 23/0           | 0.93 (0.86-0.99)           | < 0.01          |         |
| Blood vessel marker | 24/0     | 0.94 (0.88-1.00)           | < 0.01          |         |
| HHV-8    | 17/0           | 0.82 (0.72-0.91)           | < 0.01          |         |
| Macroscopic appearance |     |                           |                 |         |
| Patches | 25/4           | 0.64 (0.57-0.71)           | < 0.01          |         |
| HE       | 12/1           | 0.64 (0.57-0.71)           | < 0.01          |         |
| D2-40    | 14/0           | 0.80 (0.70-0.91)           | < 0.01          |         |
| Blood vessel marker | 15/0     | 0.83 (0.73-0.93)           | < 0.01          |         |
| HHV-8    | 8/0            | 0.67 (0.57-0.77)           | < 0.01          |         |
| Polypoid | 9/3            |                           |                 |         |
| HE       | 5/0            | 0.78 (0.61-0.95)           | < 0.01          |         |
| D2-40    | 8/0            | 0.94 (0.84-1.00)           | < 0.01          |         |
| Blood vessel marker | 8/3     | 0.44 (0.34-0.54)           | < 0.01          |         |
| HHV-8    | 4/0            | 0.72 (0.55-0.89)           | < 0.01          |         |
| SMT      | 37/7           | 0.93 (0.88-0.99)           | < 0.01          |         |
| HE       | 32/0           | 0.93 (0.88-0.99)           | < 0.01          |         |
| D2-40    | 33/0           | 0.95 (0.90-1.01)           | < 0.01          |         |
| Blood vessel marker | 33/1     | 0.88 (0.73-1.00)           | < 0.01          |         |
| HHV-8    | 30/0           | 0.91 (0.84-0.97)           | 0.15            |         |
| SMT with ulcer | 15/5      |                           |                 |         |
| HE       | 10/0           | 0.83 (0.71-0.96)           | < 0.01          |         |
| D2-40    | 10/0           | 0.83 (0.71-0.96)           | < 0.01          |         |
| Blood vessel marker | 12/0     | 0.90 (0.80-1.00)           | < 0.01          |         |
| HHV-8    | 11/0           | 0.87 (0.75-0.98)           | 0.34            |         |

1P values of receiver operating characteristic (ROC) area in each category were compared. 2P < 0.05 for the comparison with lesions by hematoxylin and eosin (HE) staining. GI-KS: Gastrointestinal Kaposi sarcoma; ROC-AUC: ROC area under the curve; SMT: Submucosal tumor.

Diagnostic value of GI-KS according to size, location, and macroscopic appearance

The ROC-AUC of four specific stains showed a tendency toward an increase in tumor staging on endoscopy (e.g., small to large, flat, protruded, and SMT appearance) (Table 3). The ROC-AUC of blood vessel marker in polypoid appearance was extremely low compared with other lesions (Table 3).

The ROC-AUC of four specific stains was significantly different in size, GI tract location, appearance of patches, and polypoid lesion for the diagnosis of GI-KS (Table 3). No significant differences were noted in the ROC-AUC of four specific stains for SMT lesions (P = 0.15) or ulcerative SMT lesions (P = 0.34) (Table 3).

Comparison of the ROC-AUC between HE staining and specific staining

The ROC-AUC of the D2-40 stain was higher than that of the HE stain for lesions < 10 mm, lesions ≥ 10 mm, upper GI tract, lower GI tract, patches, polyoids, and SMT (Table 3). Of these, upper GI tract and polypoid appearance were statistically significant (P < 0.05). The ROC-AUC of blood vessel marker or HHV-8 stain was higher than that of HE staining for lesions ≥ 10 mm, patches, and ulcerative SMT (Table 3), with no statistical significance (P > 0.05).

DISCUSSION

Previous IHC studies have shown the utility of differential diagnosis between cutaneous KS and vascular tumors such as hemangioma, lymphangioma, hemangiendothelioma, and angiosarcoma. However, development of vascular tumor in the GI tract is extremely rare. Therefore, differential diagnosis for GI-KS can be different for cutaneous and GI tract sites. In the present study, lesions that were difficult to distinguish from GI-KS are inflammation-associated protruded lesions with reddish color. The reason for this is that GI-KS can appear as a strong reddish mucosa and vary from flat maculopapular or polypoid masses to SMT, ulceration, or bulky tumor masses on endoscopy.

Previous studies investigated only GI-KS cases, and
only sensitivity can be elucidated[14-16]. In the current study, the ROC-AUC values of the four IHC stains and HE stain were > 0.8, demonstrating that all had good diagnostic accuracy. However, it is not feasible in clinical practice to diagnose KS using all stains. Based on the results of this study, we conclude that D2-40 is the only stain capable of complementing HE staining.

We found that the ROC-AUC of four specific stains tended to increase with endoscopic tumor staging (e.g., small to large, flat, protruded, and SMT). Previous studies, particularly those on cutaneous KS, have also shown that diagnostic accuracy varies according to tumor staging[9,21,22]. Although it is not feasible to apply staging classification of cutaneous KS to the evaluation of the macroscopic appearance of GI-KS, it is important--based on their results and our findings--to take tumor appearance and staging into consideration for the pathological diagnosis of KS.

We further performed subgroup analysis of four stains to reveal differences in diagnostic accuracy. No significant differences were noted in the ROC-AUC of four specific stains in SMT lesions (P = 0.15) and ulcerative SMT lesions (P = 0.34), indicating that HE staining alone is sufficient for diagnosing lesions with SMT appearance. Although we attempted to find lesions that can be better diagnosed with the addition of other IHC stains, polyoid lesions, and location of upper GI tract attained significant ROC-AUC (P < 0.05) scores with D2-40. The ROC-AUC of D2-40 was always > 0.8, regardless of the size, location, or macroscopic appearance of lesions, indicating its utility as an additional staining modality.

One of the characteristic findings of this study is that the ROC-AUC of the blood vessel marker for polyoid appearance was extremely low compared with other lesions. This was due to the presence of hyperplastic polyps, meaning that CD34 staining produces positive results due to vessel proliferation. This can result in higher false-positive cases (g = 38) and lower diagnostic accuracy of KS.

There are several limitations of the present study. First, we assessed IHC staining as positive or negative instead of using a scoring system; a semi-quantitative system might provide more accurate or available results in clinical practice. Second, positive vessel marker staining was defined as CD31- or CD34-positive because CD31 or CD34 was used by each pathologist. However, because 80% (82/103) of the lesions were examined using CD34, and because CD34 is reportedly a more accurate marker than CD31[23], we believe the results of the vessel marker staining in the present study are reliable.

In conclusion, endoscopic biopsy for diagnosing GI-KS can be performed safely. The diagnostic accuracy of HE staining, lymphatic and blood vessel endothelial cell markers, and HHV-8 was found to be high. Among these, D2-40 had the highest accuracy. The diagnostic accuracy of four specific stains tended to increase with endoscopic tumor staging. In particular, polyoid lesions and those in the upper GI tract respond well to HE staining complemented by D2-40 staining.

ACKNOWLEDGMENTS

We wish to thank Hisae Kawashiro, Clinical Research Coordinator, for assistance with data collection.

REFERENCES

1 Buchacz K, Baker RK, Paletta FJ, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24: 1549-1559 [PMID: 20502317 DOI: 10.1097/QAD.0b013e32833a3967]
2 Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeal TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654 [PMID: 16868446 DOI: 10.1097/01.aids.0000228411.75324.59]
3 Biggar RJ, Rabkin CS. The epidemiology of AIDS--related neoplasms. *Hematol Oncol Clin North Am* 1996; 10: 997-1010 [PMID: 8880192 DOI: 10.1016/s0889-8588(05)70380-4]
4 Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stallbrink HJ, Phillips AN, Lundgren JD. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. *Cancer* 2004; 100: 2644-2654 [PMID: 15197808 DOI: 10.1002/cncr.20309]
5 Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? *Lancet* 1990; 335: 123-128 [PMID: 1967430 DOI: 10.1016/S0140-6736(90)90591-6]
